Your browser doesn't support javascript.
loading
High unbound flucloxacillin fraction in critically ill patients.
Wallenburg, Eveline; Ter Heine, Rob; de Lange, Dylan W; van Leeuwen, Henk; Schouten, Jeroen A; Ten Oever, Jaap; Kolwijck, Eva; Burger, David M; Pickkers, Peter; Gieling, Emilie M; de Maat, Monique M; Frenzel, Tim; Brüggemann, Roger J.
Afiliação
  • Wallenburg E; Department of Pharmacy and Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • Ter Heine R; Department of Pharmacy and Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • de Lange DW; Department of Intensive Care and Dutch Poisons Information Center, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van Leeuwen H; Department of Intensive Care, Rijnstate, Arnhem, The Netherlands.
  • Schouten JA; Department of Intensive Care, Radboud university medical center, Nijmegen, The Netherlands.
  • Ten Oever J; Department of Intensive Care, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Kolwijck E; Radboudumc Center for Infectious Diseases, Nijmegen, The Netherlands.
  • Burger DM; Radboudumc Center for Infectious Diseases, Nijmegen, The Netherlands.
  • Pickkers P; Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands.
  • Gieling EM; Department of Medical Microbiology, Radboud university medical center, Nijmegen, The Netherlands.
  • de Maat MM; Department of Pharmacy and Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • Frenzel T; Radboudumc Center for Infectious Diseases, Nijmegen, The Netherlands.
  • Brüggemann RJ; Department of Intensive Care, Radboud university medical center, Nijmegen, The Netherlands.
J Antimicrob Chemother ; 76(12): 3220-3228, 2021 11 12.
Article em En | MEDLINE | ID: mdl-34463730
ABSTRACT

OBJECTIVES:

To describe the unbound and total flucloxacillin pharmacokinetics in critically ill patients and to define optimal dosing strategies. PATIENTS AND

METHODS:

Observational multicentre study including a total of 33 adult ICU patients receiving flucloxacillin, given as intermittent or continuous infusion. Pharmacokinetic sampling was performed on two occasions on two different days. Total and unbound flucloxacillin concentrations were measured and analysed using non-linear mixed-effects modelling. Serum albumin was added as covariate on the maximum binding capacity and endogenous creatinine clearance (CLCR) as covariate for renal function. Monte Carlo simulations were performed to predict the unbound flucloxacillin concentrations for different dosing strategies and different categories of endogenous CLCR.

RESULTS:

The measured unbound concentrations ranged from 0.2 to 110 mg/L and the observed unbound fraction varied between 7.0% and 71.7%. An integral two-compartmental linear pharmacokinetic model based on total and unbound concentrations was developed. A dose of 12 g/24 h was sufficient for 99.9% of the population to achieve a concentration of >2.5 mg/L (100% fT>5×MIC, MIC = 0.5 mg/L).

CONCLUSIONS:

Critically ill patients show higher unbound flucloxacillin fractions and concentrations than previously thought. Consequently, the risk of subtherapeutic exposure is low.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Terminal / Floxacilina Tipo de estudo: Clinical_trials / Health_economic_evaluation / Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Terminal / Floxacilina Tipo de estudo: Clinical_trials / Health_economic_evaluation / Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article